- Recruiting
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
Updated: Sep 2, 2022
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.
CHINESE STUDY
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)
Sponsor
Nanjing Legend Biotech Co.
Collaborator
ClinicalTrials.gov Identifier: NCT03758417
Official Title: A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : November 29, 2018
Click here for details on ClinicalTrials.gov
Location
China
China, Beijing
China, Fujian
China, Jiangsu
China, Shanghai
China, Shanxi
China, Sichuan
China, Zhejiang
Comentarios